Sinha Aish, Rahman Haseeb, Perera Divaka
The BHF Centre of Excellence and the NIHR Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
Cardiovasc Endocrinol Metab. 2020 Jul 16;10(1):22-30. doi: 10.1097/XCE.0000000000000223. eCollection 2021 Mar.
Coronary microvascular disease (CMD) is present in 30% of patients with angina and is associated with increased morbidity and mortality. We now have an improved understanding of the pathophysiology of CMD and the invasive and noninvasive tests that can be used to make the diagnosis. Recent studies have shown that management of CMD guided by physiological testing yields better results than empirical treatment. Despite major advances in diagnosing and stratifying this condition, therapeutic strategies remain limited and poorly defined. This review article discusses recent advances in understanding the pathophysiology of CMD, the modalities that are available to diagnose it clinically, current management options and a look at what is in store for the future.
冠状动脉微血管疾病(CMD)存在于30%的心绞痛患者中,且与发病率和死亡率增加相关。我们现在对CMD的病理生理学以及可用于诊断的侵入性和非侵入性检查有了更深入的了解。最近的研究表明,以生理检查为指导的CMD管理比经验性治疗产生更好的结果。尽管在诊断和分层这种疾病方面取得了重大进展,但治疗策略仍然有限且定义不明确。这篇综述文章讨论了在理解CMD病理生理学方面的最新进展、临床诊断可用的方法、当前的管理选择以及对未来的展望。